创伤性脑损伤中的止血障碍:从机制到管理
本综述讨论创伤性脑损伤(TBI)诱导性凝血病的机制、诊断挑战及其与血肿扩大的关联,并评估氨甲环酸、血浆、重组因子VIIa和纤维蛋白原等随机试验证据。多项研究显示概念验证,但临床获益不一致,可能与时机、异质性和研究设计把握度不足有关。未来超早期和个体化方法结合实时止血监测可能最有前景。
要点
- TBI后可诱导独特的脑源性止血反应,与全身创伤中失血性休克驱动的凝血病不同。
- TBI相关凝血病是血肿扩大和结局的决定因素,但诊断存在挑战。
- 针对凝血病的随机试验显示概念验证,但临床获益不一致,可能与时机、异质性和研究设计把握度不足有关。
核心结论
- TBI诱导性凝血病与血肿扩大和结局相关,但靶向治疗的临床获益仍不一致。
- 超早期和个体化方法结合实时止血监测可能提供最有前景的路径。
- 更好地理解凝血病的时间和机制动态对改善治疗策略和患者结局至关重要。
研究设计与样本
- 综述,讨论TBI诱导性凝血病的机制、诊断挑战及与血肿扩大的关联,并评估针对凝血病的随机试验证据。
主要发现
- TBI后凝血病日益被认为是血肿扩大和结局的决定因素。
- 与全身创伤中凝血病常由失血性休克驱动不同,TBI似乎诱导独特的脑源性止血反应。
- 针对凝血病的随机试验(包括氨甲环酸、血浆、重组因子VIIa和纤维蛋白原)显示概念验证,但临床获益不一致,可能与时机、异质性和研究设计把握度不足有关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coagulopathy following traumatic brain injury (TBI) is increasingly being recognized as a determinant of hematoma expansion and outcome. Unlike systemic trauma, where coagulopathy is often driven by hemorrhagic shock, TBI appears to induce a unique brain-derived hemostatic response. In this review, we discuss the mechanisms underlying TBI-induced coagulopathy, its diagnostic challenges, and association with hematoma expansion. We further evaluate evidence from randomized trials targeting coagulopathy in TBI, including interventions such as tranexamic acid, plasma, recombinant Factor VIIa, and fibrinogen. While several studies show proof of concept, clinical benefit remains inconsistent, likely due to issues of timing, heterogeneity, and underpowered study design. Moving forward, ultra-early and individualized approaches guided by real-time hemostatic monitoring may offer the most promising path. A better understanding of the temporal and mechanistic dynamics of coagulopathy will be essential for improving treatment strategies and patient outcomes.
引用
- Fletcher-Sandersjöö A, Sebghati J, Thelin EP, et al. Hemostatic disturbances in traumatic brain injury: from mechanism to management. Acta Neurochir (Wien). 2025. PMID: 40387974. doi:10.1007/s00701-025-06549-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。